Westlake Village-based biotech company MannKind announced that it would begin enrolling a second cohort of pediatric patients in a safety study for its inhalable insulin product Afrezza. The initial cohort studied the safety and the passage of the drug through the body in patients 13 to 17 years old and found that the outcomes were…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
